Drug intelligence / Profile preview

secretory leukocyte protease inhibitor

Development stage
Phase 1
Modality
Recombinant Proteins and Enzymes
Administration
Inhalation, Intranasal, Topical, Intraarticular, Intravenous
01

Overview

Secretory leukocyte protease inhibitor (SLPI) is a 12 kDa, non-glycosylated, cysteine-rich protein that functions as a protease inhibitor. It contains eight intramolecular disulfide bonds and is structured with two homologous domains, with the C-terminal domain exhibiting anti-protease activity. SLPI is found in bronchial, cervical, and nasal mucosa, saliva, and seminal fluids. It primarily protects tissues against inflammation by inhibiting serine proteases, especially neutrophil-derived serine proteases including cathepsin G and elastase. Beyond its protease inhibitory function, SLPI demonstrates antimicrobial properties against certain bacteria and fungi, and has shown anti-HIV-1 activity. It also exerts anti-inflammatory effects by inhibiting NF-κB activation in macrophages.

Other names
antileukoproteinaseSLPIALK1ALK-1ALK 1ALPBLPIHUSIHUSI-IMPIWAP4WAP-4WAP 4WFDC4WFDC-4WFDC 4mucus proteinase inhibitor
02

Targets

CTSG (Cathepsin G)ELANE (Human Neutrophil Elastase)CMA1 (Chymase)PRSS1 (Trypsin family)Nuclear factor kappa B DNA consensus sequence (NF-κB consensus sequence)

Beyond the preview

Go deeper on secretory leukocyte protease inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on secretory leukocyte protease inhibitor.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call